Full Title
A Phase 3, Randomized, Double-blind, Study of Belzutifan + Zanzalintinib Versus Belzutifan + Placebo in Participants with Advanced RCC who have progressed on or after both PD-1/L1 and VEGF-TKI therapies in sequence or in combination (LITESPARK-034)Purpose
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Contact
For more information or to see if you can join this study, please call Dr. Robert Motzer’s office at 646-888-4717.
Protocol
26-326
Phase
Phase III (phase 3)
Investigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT07489495
ClinicalTrials.gov